A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma
Article
Odia, Y, Sul, J, Shih, JH et al. (2016). A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma
. 5(2), 59-67. 10.2217/cns-2015-0010
Odia, Y, Sul, J, Shih, JH et al. (2016). A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma
. 5(2), 59-67. 10.2217/cns-2015-0010